Anebulo Pharmaceuticals, Inc.
OTC: ANEB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Richard Anthony Cunningham
- Employees
- 3
- Headquarters
- Lakeway, United States
- IPO year
- 2021
- Market cap
- $16.1M
- Website
- https://www.anebulo.com
Loading ANEB…
Loading profile data…Frequently asked questions about ANEB
What does Anebulo Pharmaceuticals, Inc. (ANEB) do?
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding recept...
Where does ANEB trade?
Anebulo Pharmaceuticals, Inc. (ANEB) trades on the Other OTC.
What sector is ANEB in?
Anebulo Pharmaceuticals, Inc. (ANEB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Anebulo Pharmaceuticals, Inc.?
Richard Anthony Cunningham is the chief executive officer of Anebulo Pharmaceuticals, Inc. (ANEB).
Where is Anebulo Pharmaceuticals, Inc. headquartered?
Anebulo Pharmaceuticals, Inc. is headquartered in United States.
Does ANEB pay a dividend?
Anebulo Pharmaceuticals, Inc. (ANEB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ANEB go public?
Anebulo Pharmaceuticals, Inc. (ANEB) completed its initial public offering in 2021.